Elution Profiles of Antibody-Drug Conjugates in Preparative Chromatography

Takuro TANAKA¹,², Koichiro IKEDA¹,², Shuichi YAMAMOTO¹,², and Noriko YOSHIMOTO¹,²*  

¹Department of Applied Chemistry, Graduate School of Science and Technology for Innovation, Yamaguchi University, Tokiwadai 2-16-1, Ube 755-8611, Japan.  
²Manufacturing Technology Association of Biologics, Shinkawa 2-6-16, Chuoku, Tokyo 104-0033, Japan

Abstract Monoclonal antibody drug conjugate (ADCs) have received much attention as pharmaceutical agents for treating serious diseases such as cancer. However, it is difficult to separate them on the basis of the drug to antibody ratio, DAR. Hydrophobic chromatography (HIC) is commonly used for the analysis of the drug to antibody ratio, DAR. The retention of ADCs on HIC can be controlled by the hydrophobic nature of ADCs, depending on the mobile phase conditions. They are sometimes performed at the restricted conditions where the solubility is too low. Ion exchange chromatography (IEC) using electrostatic interaction is an orthogonal method to HIC. IEC is widely used because of its higher capacity than HIC. We investigated the retention behavior of the protein conjugated with surrogate drugs on IEC. The surrogate drugs employed are 7-diethylamino-3-[4'-maleimidylphenyl] 4-methylcoumarin (CPM), N-(1-pyrenyl) maleimide (NPM). Bovine serum albumin (BSA) was used as a model protein. The molar ratio (CPM and NPM to protein) was set to 3. The maleimide group of CPM and NPM reacts with the thiol group of the proteins. On the linear gradient elution experiments, the elution salt concentrations of the conjugated and non-conjugated proteins were measured to obtain chromatographic parameter of the number of binding sites, B.

1 Introduction

PEGylated proteins and monoclonal antibody drug conjugates (ADCs) are considered as next generation biopharmaceuticals. The conjugated flexible PEG layers contribute to protect the proteins from the lytic actions of immune system cells and proteases (Abuchowski et al., 1977). Furthermore, the above chemically-modified proteins are large enough in their hydrodynamic diameters to escape from the kidney excretion system, which allows their long in vivo half-life. ADCs are designed to bind to cancer-specific antigens via antigen-antibody interaction causing the death of target cells effectively (Gordon et al., 2015). The same chemical reactions can be employed in the preparation of PEGylated proteins and ADCs (Gordon et al., 2015; Fee and van Alstine, 2006). Lysine residue, which is one of the most abundant amino acids on the protein surface, is modifiable with acylating derivatives or ADCs which have activated functional groups such as succinimidyl carbonate and aldehyde (Bonora and Drioli, 2009). Since multiple lysine residues of proteins are involved in the reactions, the product is heterogeneous in the number of modified PEGs or drugs per protein. For the site-specific conjugation, the reactions between cysteine residues and the derivatives of malamide and iodoacetamide, (Bonora and Drioli, 2009) can be employed since the number of cysteine residues on a protein surfaces is much smaller than that of lysine ones. On the other hand, the loss in the activity both of protein and drugs are undesirably observed even in the site-specific conjugation reactions. As for the PEGylated proteins with biological activity, the number of PEG conjugated to a protein molecule affects the activity. As for the ADCs, the drug to antibody ratio, DAR, significantly affects the potency, such as the binding capacity and cytotoxicity. Therefore, the purification of these protein conjugates, PEGylated protein and ADCs is of critical importance in their production processes. The protein molecules can be purified on the basis of their size, shape, surface charge and hydrophobicity. Ultrafiltration, diafiltration and chromatography can be applied for the purification of modified proteins. Ion exchange chromatography, IEC is the most common technique for the separation of PEGylated proteins (Fee and van Alstine, 2006). The retention time of PEGylated proteins on IEC becomes shorter than that of unmodified ones because of the charge shielding and steric hindrance effects caused by the conjugated PEG. The IEC separation can, therefore, offer the opportunity of the separation of protein isomers on the basis of the number and position of PEG conjugated (Yoshimoto and Yamamoto 2012; Yoshimoto et al., 2013). We reported that the number of binding sites, B to the ion exchange ligands is practically

* Corresponding author: noriko-y@yamaguchi-u.ac.jp

© The Authors, published by EDP Sciences. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (http://creativecommons.org/licenses/by/4.0/).
unchanged between the PEGylated and unmodified proteins even when the charge shielding effect of PEG chains weakens the electrostatic interaction between the PEGylated proteins and the ligand. For the purification of ADCs, hydrophobic interaction chromatography is commonly used because the proteins tend to become hydrophobic through the conjugation with drugs (Andris et al., 2018). So far, IEC is rarely used for the purification of ADCs, as their charge properties are poorly understood.

In this study, the charge properties of ADCs were investigated based on their retention profiles on IEC. Bovine serum albumin (BSA), which has free cysteine residues on the surface, was employed as a model protein to be modified with drugs to give model ADCs. Pyren and coumarin were employed as surrogate hydrophobic drugs for the preparation of ADC as reported previously (Andris et al., 2018). The drug-modified BSA was characterized in terms of their number of binding sites and retention mechanism on IEC.

2 Experimental

2.1 Chemicals

Bovine serum albumin monomer (BSA monomer, SIGMA, #A1900) was used as model proteins. The surrogate drugs employed were 7- diethylamino-3-(4’-maleimidylphenyl)-4-methylcoumarin (CPM, ALDRICH, #C1484-25MG) and N-(1-pyrenyl) maleimide (NPM, ALDRICH, #P7908-500MG). L-cysteine (Nakaraitesuku, #10309-12) was used as a terminator of conjugation reactions.

2.2 Conjugation reaction

BSA monomer solution in 50 mM sodium phosphate buffer ( pH7.2, buffer A) containing 10% dimethyl sulfoxide (DMSO) was prepared at a concentration of BSA of 2 mg/mL. The stock solution of CPM and NPM (Table 2) was prepared at a concentration of 1 mg/mL in DMSO. The BSA solution (5.1 mL) was mixed with a 0.187 mL of CPM solution or a 0.0934 mL of NPM solution to give the molar ratio (CPM and NPM to protein) of 3. The reaction solutions were mixed gently overnight at 25 °C. For the termination of the reaction, 0.1 mL of 10 mg/mL L-cysteine solution in 50 mM sodium phosphate buffer containing 10% of DMSO was added to the reaction mixture followed by mixing gently for 30 min at 25 °C.

2.3 Ion exchange chromatography

The ion exchange chromatography (IEC) analyses of the reaction mixtures were performed with AKTA pure 25M (GE Healthcare). The linear salt concentration gradient elution was carried out by changing NaCl concentrations from 0.03 to 1 M. Hitrap Q Sepharose HP (Table 1) (1 mL) was used as an anion exchange column. Sample volume was 0.1 mL and flow rate was 1 mL/min. Mobile phase was 10 mM Tris-HCl buffer solution (pH 7.0) containing 30 mM or 1 M NaCl.

2.4 Size exclusion chromatography

Size exclusion chromatography was performed with AKTA pure 25M (GE Healthcare). Mobile phase was Tris-HCl buffer solution (pH 7.0) containing 100 mM NaCl (pH 8.0). TSK G3000 SW and TSK G3000 PW (Table 1) were used as stationary phase. The sample volume was 0.1 mL, and the flow rate was 0.5 mL/min.

Table 1. Characteristics of columns.

| Column          | Z [cm] | d [cm] | ε | dp [µm] | Supplier     |
|-----------------|--------|--------|---|---------|--------------|
| IEC Q Sepharose HP | 2.5    | 1.1    | 0.3 | 34      | GE healthcare|
| SEC TSK G3000SW  | 30     | 0.75   | 10 | Tosoh   |
| SEC TSK G3000PW  | 30     | 0.78   | 7  | Tosoh   |

Table 2. Surrogate drugs used.

| Surrogate drug | Chemical structure |
|----------------|--------------------|
| CPM            | 7-diethylamino-3-(4’-maleimidylphenyl)-4-methylcoumarin |
| NPM            | N-(1-pyrenyl) maleimide |

2.5 UV absorption measurement

The fraction was collected, and analyzed by using a micro-plate reader at the wavelength ranging from 200 to 700 nm with Power Wave XS Microplate Reader (Bio Tek). UV-STAR® MICRO-PLATE, and 96 WELL (Bio-One, #655801) were used for measuring the absorbance of solutions at each volume of 0.2 mL.

3. Results and Discussion

3.1 Analysis of UV/VIS absorption spectra of conjugation reaction mixtures

Figure 1 shows the UV/VIS absorption spectra of native BSA and the reaction mixtures containing BSA and CPM or NPM. Absorption peaks are observed around 280 nm for both native BSA and the BSA-containing reaction mixtures. The additional peaks were observed around 400 nm with respect to BSA-NPM reaction mixture, and around 340 nm with BSA-CPM, respectively. Therefore, these wavelengths were employed to investigate the BSA conjugates elution profiles on the chromatography column in the following.
3.2 Analysis of the protein surface charge by ion exchange chromatography

3.2.1 Linear salt concentration gradient elution

Figure 2 shows that the elution curves of the linear salt gradient experiments (LGE) obtained with respect to BSA and CPM mixture containing cysteine used for terminating the reactions (a) and L-cysteine and CPM one without BSA (b). As shown in Fig. 1, UV signals both at 280 nm and at 400 nm are attributed to the conjugation of BSA or cysteine with CPM in the elution curves. In both Figures (a) and (b) the small elution peaks are seen at the elution volume of about 10 mL. The peaks correspond to cysteine-CPM conjugates. In Fig. 2(a), the later large peak corresponds to the BSA-CPM conjugates. The elution volume of the large peak was slightly larger than that of native BSA (data not shown), and the volume increased as the gradient volume increased. The elution salt concentrations, \( I_R \) in LGE correlated with the normalized gradient volume \( \text{GH} = (I_f - I_0)/\epsilon \times \frac{V_g}{V_t} (1 - \epsilon) \), \( I_f \) and \( I_0 \): final and initial salt concentrations in LGE, \( V_g \): gradient volume, \( V_t \): column volume, \( \epsilon \): column porosity) (Figure 3). The correlation curve was fitted by using following equation,

\[
GH = I_R^{(b+1)}/\{A(B+1)\} \tag{1}
\]

where \( A \) is a constant including equilibrium constant of ion exchange reaction, \( B \) is the number of binding site, \( K_c \) and ion exchange ligand density, \( \Lambda (A = K_c \Lambda^3) \). Similar elution profiles were observed with BSA-NPM reaction mixtures (data not shown). From the slopes of these correlation curves (GH-\( I_R \) curves, Yamamoto, et al., 2012 and 2013), the number of binding sites can be determined as shown in Table 3.

| Table 3 The number of binding site, \( B \). |
|------------------|
| BSA | 6.5 |
| BSA-CPM | 7.5 |
| BSA-NPM | 7.4 |
3.2.2 Size exclusion chromatography of conjugates

Figure 4 shows the elution curves of native BSA and the reaction mixture containing BSA-CPM or BSA-NPM on the size exclusion columns packed with TSK G3000 SW (a) and TSK G3000 PW XL (b). With the TSK G3000 SW column, the dimer and monomer BSA are separated into two peaks (Fig. 4 (a)). The intensities of the absorbance increased confirming the conjugation of CPM and NPM to BCA. However the aggregate of the conjugates is not seen. These results imply that the aggregate of conjugates was little formed in the SEC column.

4 Conclusion

Surrogate drugs (CPM and NPM) were successfully conjugated to thiol groups of BSA. In LGE experiments, the elution concentrations of the BSA-CPM and BSA-NPM conjugates were slightly increased than the concentration determined with respect to native BSA. The number of binding sites was 7.4 for BSA-CPM and 7.5 for BSA-NPM. The values were larger than the value of BSA (6.5), suggesting the aggregation of conjugates on the surface of ion exchange resin.

Acknowledgment

This research was supported by AMED under Grant Number JP18063169.

References

Abuchowski, A., T. van Es, N. C. Palczuk, and F. F. Davis; “Alteration of Immunological Properties of Bovine Serum Albumin by Covalent Attachment of Polyethylene Glycol,” J. Biol. Chem., 252, 3578–3581 (1977).

Andris, S., M. Wendeler, X. Wang, and J. Hubbuch; “Multi-step High-throughput Conjugation Platform for the Development of Antibody-Drug Conjugates,” J. Biotechnology, 278, 48–55 (2018).

Caliceti, P. and F. M. Veronese; “Pharmacokinetic and Biodistribution Properties of poly(ethylene glycol)-protein Conjugates,” Adv. Drug Deliv. Rev., 26, 1261–1277 (2003).

Fee, C. J. and J. M. van Alstine; “PEG-proteins: Reaction Engineering and Separation Issues,” Chem. Eng. Sci., 61, 924–939 (2006).

Gordon, M. C., L. Li, J. Zhuang, B. Osborne and S. Thayumanavan; “Field Guide to Challenges and Opportunities in Antibody-drug Conjugates for Chemists,” Bioconjug. Chem., 26, 2198–2215 (2015).

Yoshimoto, N. and S. Yamamoto; “PEGylated Protein Separations: Challenges and Opportunities,” Biotechnol. J., 7, 592–593 (2012).

Yoshimoto, N., Y. Isakari, D. Itoh, and S. Yamamoto; “PEG Chain Length Impacts Yield of Solid-phase Protein PEGylation and Efficiency of PEGylated Protein Separation by Ion-exchange Chromatography: Insights of Mechanistic Models,” Biotechnol. J., 8, 801–810 (2013).